StimLabs’ umbilical cord-derived wound care product launches in the US

StimLabs has launched Corplex P in the United States. Corplex P is the first and only medical device derived from the extracellular matrix (ECM) of the human umbilical cord. Corplex P is reportedly the first human birth tissue product to receive US Food and Drug Administration (FDA) approval.

Corplex P is a dehydrated human umbilical cord particle (dHUCP) device designed to treat difficult-to-heal wounds. The main advantages of the device lie in its composition, configuration and ability to regulate moisture exchange.

The components of Corplex P’s connective tissue matrix, approved by the FDA in February, include collagens, fibronectin, laminin proteoglycans and glycosaminoglycans (GAGs). The proprietary processing technique that enables the preservation of these components distinguishes Corplex P from many xenograft products whose processing techniques can result in the removal of valuable GAGs and proteoglycans.¹ Its hydrophilic components, particularly hyaluronic acid, are crucial to the device’s absorption properties. While the product composition gives Corplex P the ability to create a moist wound environment, its particle format enables further moisture management by allowing exudate to drain from the wound. The particle configuration also provides adaptability and wound bed contact, allowing Corplex P to be more easily integrated into the wound during healing.

Corplex P treats a wide range of wound types, including partial and full wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds and weeping wounds.

“Chronic and acute wounds represent a major healthcare challenge and affect millions of people each year,” said John Daniel, founder and CEO of StimLabs. “With Corplex P, StimLabs aims to address this challenge by offering physicians and patients an advanced wound management solution. Corplex P offers an opportunity for a better quality of life for people in need of care, and since its limited release, healthcare professionals have been thrilled by the impact it is having. We are pleased to now make this available nationwide.”

Corplex P offers numerous advantages: It is optimized for complex and irregular wound beds; it provides a complex, porous framework; and it absorbs naturally into the wound. The product also ensures a moist wound environment by regulating moisture exchange and the particle format enables a versatile application process and more efficient product use.*

“StimLabs has done something unique by bringing a human tissue-derived device to market. “Corplex P is not only rich in biologically important components, but the format also allows me to tailor the product to my patients’ wounds,” noted Jamison Feramisco, MD, Ph.D. “I am treating a non-contiguous venous ulcer and I can do this.” I can use my product more efficiently while ensuring ideal wound coverage. The particles can be applied at different densities and moisture levels*, allowing me to pack them into tunneling wounds or use them on larger, more superficial wounds, such as MASD. Corplex P complements my treatment algorithm for difficult-to-heal wounds and I look forward to seeing how many of my patients can benefit from this technology.”

Corplex P is available for use in hospital settings.

Stimlabs LLC was founded in 2015 to advance regenerative medicine. StimLabs is comprised of industry leaders and is committed to providing patients with the best possible care through innovation and personalized solutions. StimLabs has a product portfolio that meets various clinical needs and has built a strong catalog of intellectual property.

*For detailed information on product safety and device application, please refer to the instructions for use.

reference

¹ Cissell DD, Hu JC, Griffiths LG, Athanasiou KA Antigen removal to produce biomechanically functional xenogeneic tissue transplants. J. Biomech. 2014;47:1987–1996. doi: 10.1016/j.jbiomech.2013.10.041.